The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Highlights in lung cancer at ESMO 2022
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses her highlights presented in the field of lung cancer at the European Society for Medical Oncology (ESMO) 2022 Congress, including long-term follow-up data from multiple trials and updates in novel targeted therapies such as sotorasib. Dr Johnson additionally talks on the Phase III CANOPY-A trial (NCT03447769) of canakinumab in patients with non-small cell lung cancer (NSCLC), which failed to meet its primary endpoint. This interview took place at the ESMO 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
